Why Clean Tech Is Taking Biotech's Shine

It's simple: Alternative energy is where the venture capital is these days. Plus, the skill sets are similar, and researchers are making the jump

Nigel Beeley is a biopharma veteran. He spent 25 years in research at such biotechnology companies as Amylin Pharmaceuticals (AMLN), Arena Pharmaceuticals (ARNA), and Senomyx (SNMX). He had a hand in creating cancer and metabolic disease drugs Mylotarg, Symlin, Byetta, and Lorcaserin. But when he decided to start his own company based on pharmaceutical discoveries, he made a switch to a field many might find surprising: emerging alternative energy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.